Net loss: US$12.2m (loss widened by 100% from 3Q 2023). US$0.28 loss per share. Revenue exceeded analyst estimates by 10.0%. Earnings per share (EPS) missed analyst estimates by 23%. Looking ahead, ...

VYN201 Phase 2b vitiligo trial exceeds enrollment target; Expected to be fully enrolled in December 2024 with top-line results on track for ...

VYNE Therapeutics (VYNE) delivered earnings and revenue surprises of -20.83% and 10%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Analyst Joseph Pantginis of H.C. Wainwright maintained a Buy rating on VYNE Therapeutics (VYNE – Research Report), retaining the price target of $5.75. Joseph Pantginis has given his Buy rating due to ...

A historic, Grade II listed gate at The Vyne National Trust will be restored using original timber after permission was ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

With Wolf Hall returning to the small screen this week, I predict a sudden revival of the Tudor aesthetic. Sadly, I don’t ...

VYNE Therapeutics, Inc. engages in the manufacture of pharmaceutical products. It develops and commercializes solutions using its proprietary Molecule Stabilizing Technology. Its commercial ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...